NIKKEI 225
26,659.75 +112.70 (+0.42%) HANG SENG
20,602.52 +652.31 (+3.27%) CRUDE OIL
112.38 -1.82 (-1.59%) GOLD FUTURES
1,813.80 -0.20 (-0.01%) DOW
32,625.15 +401.73 (+1.25%) BTC-GBP
23,843.74 -173.08 (-0.72%)
Apontis Pharma AG (APPH.F)
- EQS Group
APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities
DGAP-News: APONTIS PHARMA AG / Key word(s): AGM/EGMAPONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities 12.05.2022 / 15:00 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majoritiesMonheim am Rhein, 12 May 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single
- EQS Group
APONTIS PHARMA continues strong profitable growth in Q1 2022
DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim StatementAPONTIS PHARMA continues strong profitable growth in Q1 2022 10.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA continues strong profitable growth in Q1 2022 Single Pill revenues +40% to EUR 8.7 million remain main growth driver Single Pill revenue share increases to 61% (3M 2021: 57%) Total revenues grow faster than pharma sector by 31% to EUR 14.3 million EBITDA increas
- EQS Group
APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights
DGAP-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights 05.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights Further expansion of the mid-term Single Pill portfolio for the treat
